

INTERVET/SCHERING-PLOUGH ANIMAL HEALTH COMPLETES DELIVERY OF 12 MILLION DOSES OF FOOT-AND-MOUTH DISEASE VACCINE TO THE GOVERNMENT OF SOUTH KOREA

Boxmeer (the Netherlands), March 4, 2011 – Intervet/Schering-Plough Animal Health announces today that it has shipped 12 million doses of foot-and-mouth disease (FMD) vaccine to South Korea to assist in the country’s efforts to halt the ongoing FMD outbreak.

Since early January 2011, when Intervet/Schering-Plough Animal Health in South Korea received the initial request from the South Korean government, the company has provided cumulatively close to half of all FMD vaccine doses that have been delivered to the country to date. The 12 million doses of DECIVAC[®] FMD DOE, an inactivated oil-adjuvanted vaccine, have been produced at the company’s international competence center for FMD vaccine research, development and production in Cologne (Germany).

Dr. Klaus Kriebitzsch, Site Director of the FMD facility explains: “Our vaccine site in Cologne has again demonstrated its capability to respond to a short-term demand in an emergency situation by quickly upscaling the production, release and packaging processes of FMD vaccine.”

Paul van Aarle, DVM, Director Institutional Sales at Intervet/Schering-Plough Animal Health adds: “We are extremely proud to have proven once again that we are ready to address emergencies, deliver the required vaccine, meeting agreed quantities and timelines and thereby helping the government of South Korea to battle the current FMD epidemic.”

Since the FMD outbreak was reported by the South Korean government in November 2010, more than 3 million pigs, cattle, goats and deer have been culled. Late December 2010 the South Korean Ministry for Food, Agriculture, Forestry and Fisheries decided to start vaccinating all 13 million livestock in the country after initial measures were not effective in controlling the *more*

outbreak. It is anticipated that the ongoing large scale vaccination campaign will soon show result in control of the outbreak in concert with the other measures applied.

ENDS

About Foot-and-Mouth Disease

Foot and Mouth Disease (FMD) is an acute, highly contagious viral infection of cloven-hoofed animals such as cattle, sheep and pigs. FMD is not transmissible to humans but the disease has major economic consequences for farmers and governments. In the past, FMD outbreaks in non-endemic countries have been controlled through the mass culling of infected and in contact animals. New legislation and the development of marker vaccines and test kits allows for the use of vaccination as part of a FMD control strategy. FMD is characterized by vesicular lesions, followed by erosions of the epithelium of the mouths, nostrils, muzzle, feet, teats, udder, and rumen pillars. The disease is endemic in Asia, Africa and most of Latin America. At this moment countries in the European Union, North and Central America, the Caribbean, Australia, New Zealand, and many of the islands of Oceania are free of FMD. For more information, visit www.foot-and-mouth-disease.com.

About Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative animal health portfolios, including products to prevent, treat and control disease in all major farm and companion animal species as well as products for reproduction management. Intervet/Schering-Plough Animal Health; subsidiaries of Merck & Co. Inc., Whitehouse Station NJ, USA. For more information, visit www.intervet.com.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.